Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
BUSINESS
Opdivo Sales Dip 13% despite 1.5-Fold Volume Growth: Ono
Ono Pharmaceutical’s immuno-oncology star Opdivo (nivolumab) saw its sales dwindle 13% to 90.1 billion yen in the year ended March 2018, despite a 45% volume increase, as it took a full-year blow from a 50% emergency price slashed imposed in…
To read the full story
Related Article
- Ono Chief Touts 3-Pronged Recipe for Opdivo Comeback as I/O Pioneer
May 10, 2019
- Ono Racks Up 19% Revenue Rise on Positive Opdivo Sales
November 2, 2018
- Ono to Boost Oncology Reps to Prep for Opdivo Label Expansions
May 11, 2018
- Opdivo’s Half-Year Sales Sag as 50% Price Cut Takes Toll: Ono
November 7, 2017
- Ono Lifts Half-Year Guidance on Opdivo Boon
October 27, 2017
- Opdivo Drives Ono to Record Profits in FY2016
May 15, 2017
BUSINESS
- Astellas on Track to Hit 30% Margin Goal Early after Strong H1 Scorecards
November 5, 2026
- Nxera Inks US$1.47 Billion Deal with AbbVie for IBD Drug
November 5, 2026
- Kissei Might Revise Midterm Targets as Tavneos Faces Approval Revocation
November 5, 2026
- Boehringer, Lung Cancer Society Launch 5-Year Hernexeos Real-World Study
November 5, 2026
- ASKA Snags Japan Rights to Minghui’s TED Therapy
November 5, 2026
Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…